[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

ACUTE MYELOID LEUKEMIA

Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition

Leukemia volume 36, pages 2621–2633 (2022)Cite this article

Subjects

Abstract

The FLT3-ITD mutation is associated with poor prognosis in acute myeloid leukemia (AML). FLT3 tyrosine kinase inhibitors (TKIs) demonstrate clinical efficacy but fail to target leukemia stem cells (LSC) and do not generate sustained responses. Autophagy is an important cellular stress response contributing to hematopoietic stem cells (HSC) maintenance and promoting leukemia development. Here we investigated the role of autophagy in regulating FLT3-ITD AML stem cell function and response to TKI treatment. We show that autophagy inhibition reduced quiescence and depleted repopulating potential of FLT3-ITD AML LSC, associated with mitochondrial accumulation and increased oxidative phosphorylation. However, TKI treatment reduced mitochondrial respiration and unexpectedly antagonized the effects of autophagy inhibition on LSC attrition. We further show that TKI-mediated targeting of AML LSC and committed progenitors was p53-dependent, and that autophagy inhibition enhanced p53 activity and increased TKI-mediated targeting of AML progenitors, but decreased p53 activity in LSC and reduced TKI-mediated LSC inhibition. These results provide new insights into the role of autophagy in differentially regulating AML stem and progenitor cells, reveal unexpected antagonistic effects of combined oncogenic tyrosine kinase inhibition and autophagy inhibition in AML LSC, and suggest an alternative approach to target AML LSC quiescence and regenerative potential.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Autophagy inhibition reduces growth of FLT3-ITD cells and enhances sensitivity to TKI treatment in vitro.
Fig. 2: Autophagy inhibition reduces human FLT3-ITD AML CD34+ cell growth and enhances TKI sensitivity in vitro.
Fig. 3: Autophagy inhibition enhances TKI-mediated targeting of primary human FLT3-ITD cells engrafted in immunodeficient mice.
Fig. 4: Autophagy inhibition enhances TKI-mediated inhibition of FLT3 ITD AML progenitors and increases AML stem cell cycling in a genetic mouse model.
Fig. 5: Autophagy inhibition reduces repopulating capacity of FLT3-ITD AML stem cells in a genetic mouse model.
Fig. 6: Enhanced mitochondrial respiration gene signatures in AML LSC following autophagy inhibition.
Fig. 7: Reduced mitochondrial respiration in AML stem cells with tyrosine kinase inhibition in combination with autophagy inhibition.
Fig. 8: Autophagy inhibition differentially modulates p53 activity in TKI-treated FLT3-ITD AML progenitor and stem cells.

Similar content being viewed by others

Data availability

RNA sequencing data is deposited in NCBI’s Gene Expression Omnibus (GEO) and is accessible through GEO Series accession number: GSE169750.

References

  1. Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017;129:1577–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.

    Article  Google Scholar 

  3. Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014;28:1586–95.

    Article  CAS  PubMed  Google Scholar 

  4. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019;381:1728–40.

    Article  CAS  PubMed  Google Scholar 

  5. Levis M, Perl AE. Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv. 2020;4:1178–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485:260–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20:984–97.

    Article  CAS  PubMed  Google Scholar 

  8. Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19:349–64.

    Article  CAS  PubMed  Google Scholar 

  9. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013;368:651–62.

    Article  CAS  PubMed  Google Scholar 

  10. Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. Cell. 2011;146:682–95.

    Article  CAS  PubMed  Google Scholar 

  11. Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, et al. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature. 2013;494:323–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ho TT, Warr MR, Adelman ER, Lansinger OM, Flach J, Verovskaya EV, et al. Autophagy maintains the metabolism and function of young and old stem cells. Nature. 2017;543:205–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Galluzzi L, Pietrocola F, Levine B, Kroemer G. Metabolic control of autophagy. Cell. 2014;159:1263–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, Sadighi-Akha E, et al. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med. 2011;208:455–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. White E. Autophagy and p53. Cold Spring Harb Perspect Med. 2016;6:a026120.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Rothe K, Porter V, Jiang X. Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions. Int J Mol Sci. 2019;20:461.

    Article  CAS  PubMed Central  Google Scholar 

  17. Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Buhler C, et al. RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. Leukemia. 2018;32:2189–202.

    Article  CAS  PubMed  Google Scholar 

  18. Folkerts H, Hilgendorf S, Wierenga ATJ, Jaques J, Mulder AB, Coffer PJ, et al. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia. Cell Death Dis. 2017;8:e2927.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chen X, Clark J, Wunderlich M, Fan C, Davis A, Chen S, et al. Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine. Autophagy. 2017;13:955–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Liu Q, Chen L, Atkinson JM, Claxton DF, Wang HG. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model. Cell Death Dis. 2016;7:e2361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, et al. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood. 2016;127:882–92.

    Article  CAS  PubMed  Google Scholar 

  22. Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J, et al. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia. 2014;28:577–88.

    Article  CAS  PubMed  Google Scholar 

  23. Baquero P, Dawson A, Mukhopadhyay A, Kuntz EM, Mitchell R, Olivares O, et al. Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia. 2019;33:981–94.

    Article  CAS  PubMed  Google Scholar 

  24. Helgason GV, Karvela M, Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood. 2011;118:2035–43.

    Article  CAS  PubMed  Google Scholar 

  25. Karvela M, Baquero P, Kuntz EM, Mukhopadhyay A, Mitchell R, Allan EK, et al. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. Autophagy. 2016;12:936–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sumitomo Y, Koya J, Nakazaki K, Kataoka K, Tsuruta-Kishino T, Morita K, et al. Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia. Blood. 2016;128:1614–24.

    Article  CAS  PubMed  Google Scholar 

  27. Porter AH, Leveque-El Mouttie L, Vu T, Bruedigam C, Sutton J, Jacquelin S, et al. Acute myeloid leukemia stem cell function is preserved in the absence of autophagy. Haematologica. 2017;102:e344–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci USA. 2012;109:8253–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Xie M, Kong Y, Tan W, May H, Battiprolu PK, Pedrozo Z, et al. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation. 2014;129:1139–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, et al. BCAT1 restricts alphaKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature. 2017;551:384–8.

    Article  CAS  PubMed  Google Scholar 

  31. Abraham A, Qiu S, Chacko BK, Li H, Paterson A, He J, et al. SIRT1 regulates metabolism and leukemogenic potential in CML stem cells. J Clin Investig. 2019;129:2685–701.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Cook AM, Li L, Ho Y, Lin A, Li L, Stein A, et al. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. Blood. 2014;123:2826–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Kaizuka T, Morishita H, Hama Y, Tsukamoto S, Matsui T, Toyota Y, et al. An Autophagic Flux Probe that Releases an Internal Control. Mol Cell. 2016;64:835–49.

    Article  CAS  PubMed  Google Scholar 

  34. Heydt Q, Larrue C, Saland E, Bertoli S, Sarry JE, Besson A, et al. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia. Oncogene. 2018;37:787–97.

    Article  CAS  PubMed  Google Scholar 

  35. Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 2015;27:502–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Li L, Wang ZV, Hill JA, Lin F. New autophagy reporter mice reveal dynamics of proximal tubular autophagy. J Am Soc Nephrol. 2014;25:305–15.

    Article  CAS  PubMed  Google Scholar 

  37. Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540:433–7.

    Article  CAS  PubMed  Google Scholar 

  38. van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019;176:1265–81.e1224.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Folmes CD, Dzeja PP, Nelson TJ, Terzic A. Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell. 2012;11:596–606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Hsu P, Qu CK. Metabolic plasticity and hematopoietic stem cell biology. Curr Opin Hematol. 2013;20:289–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, et al. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. 2018;23:86–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Nguyen TD, Shaid S, Vakhrusheva O, Koschade SE, Klann K, Tholken M, et al. Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy. Blood. 2019;133:168–79.

    Article  CAS  PubMed  Google Scholar 

  43. Xie Y, Li J, Kang R, Tang D. Interplay Between Lipid Metabolism and Autophagy. Front Cell Dev Biol. 2020;8:431.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Investig. 2009;119:1109–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Helgason GV, Mukhopadhyay A, Karvela M, Salomoni P, Calabretta B, Holyoake TL. Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Curr Cancer Drug Targets. 2013;13:724–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Tholken M, et al. Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia. 2022;36:2396–2407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Martin KR, Celano SL, Solitro AR, Gunaydin H, Scott M, O’Hagan RC, et al. A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress. iScience. 2018;8:74–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ronan B, Flamand O, Vescovi L, Dureuil C, Durand L, Fassy F, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol. 2014;10:1013–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by NIH grant R01 CA172447 and R01 CA248794 to RB. We thank Drs Victor Darley-Usmar and Balu Chacko at the Comparative Mitochondrial Health Assessment Core for the cellular bioenergetics assays. We thank Vidya Sagar Hanumanthu for providing help with FACS sorting at the UAB Comprehensive Flow Cytometry Core; the UAB Animal resources Center for maintaining mice colonies; Maya Robinson and Amanda Mullens for obtaining and processing human samples; Mason Harris for assistance with animal studies. Immunofluorescence imaging was performed at the High-Resolution Imaging Facility at UAB.

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA

    Shaowei Qiu, Harish Kumar, Chengcheng Yan, Hui Li, Andrew J. Paterson, Nicholas R. Anderson, Jianbo He, Rui Lu, Robert S. Welner & Ravi Bhatia

  2. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China

    Shaowei Qiu

  3. Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA

    Jing Yang & Min Xie

  4. Genomics Core Facility, University of Alabama at Birmingham, Birmingham, AL, USA

    David K. Crossman

Authors
  1. Shaowei Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harish Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chengcheng Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrew J. Paterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicholas R. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jianbo He
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jing Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Min Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. David K. Crossman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Rui Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Robert S. Welner
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ravi Bhatia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: SQ, RB; Methodology: SQ, HK, CY, AP, NA, and RB; Investigation: SQ, HK, NA, HL, JH, JY, MX, DC, RL, RW, and RB; Formal analysis: SQ, RB; Writing–Original Draft: SQ, RB; Writing–Review & Editing: RB, SQ, AP; Funding Acquisition: RB; Supervision: RB.

Corresponding author

Correspondence to Ravi Bhatia.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qiu, S., Kumar, H., Yan, C. et al. Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition. Leukemia 36, 2621–2633 (2022). https://doi.org/10.1038/s41375-022-01719-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-022-01719-6

Search

Advanced search

Quick links